Gene Panel Market Share

On the basis of geographical analysis, the gene panel market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa industry is predicted to dominate majority revenue share by 2036, propelled by rising cases of genetic diseases in the region, led by lack of proper nutrition and care during pregnancy, and presence of carcinogens in the immediate surroundings. According to the data by the Eastern Mediterranean Health Journal of the World Health Organization (WHO), genetic disorders and congenital abnormalities appear in about 2%-5% of all live births in the region, causing around 50% of the total childhood deaths.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on the back of presence of major market players in the region, high healthcare expenditure, and government initiatives to curb the cancer death toll.

Frequently Asked Questions (FAQ)

The growing cases of genetic diseases and cancer globally, along with advancement in genetic technology to boost the market growth.

The market is anticipated to attain a CAGR of ~22% over the forecast period, i.e., 2022 â€“ 2030.

Lack of health awareness in developing countries is estimated to hamper the market growth.

The market in the North America is estimated to provide more business opportunities owing to the high healthcare expenditure in the region.

The major players in the market are Illumina, Inc., BGI Group, Agilent Technologies, Inc., Eurofins Scientific, QIAGEN, GENEWIZ Japan Corp., Novogene Corporation, F. Hoffmann-La Roche AG, Personalis Inc., and others.

Gene Panel Market Share